Paclitaxel/epirubcin/carboplatin
PreclinicalSmall molecule
Paclitaxel/epirubcin/carboplatin is one of 52 small molecule programs targeting Endometrial Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Endometrial Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Lenvima
EisaiPhase 3
Depo-Provera
Eli LillyPhase 3
Paraplatin
AAvyxa
Phase 3
Herceptin
OOrganon and Co
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Keytruda
Merck & Co.Phase 2
Megace
Bristol-Myers SquibbPhase 2
Femara
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSohag University